• Feature

    1. NoImage
      Photo:

      Psoriasis Infographic

      See below for PDF version

    2. NoImage
      Photo:

      IL-17A Infographic

      See below for PDF version

  • Media

    1. NoImage
      Photo:

      A Psoriasis Patient at Baseline

    2. NoImage
      Photo:

      Psoriasis Patient Achieves PASI 75

    3. NoImage
      Photo:

      Psoriasis Patient Achieves PASI 90

  • Related Documents

    1. Backgrounder: Psoriasis

    2. Backgrounder: IL-17A in Psoriasis

    3. Psoriasis Infographic

    4. IL-17A Infographic

  • Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients

  • ·  Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A1,2

    ·  Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis3

    ·  Approval based on the efficacy and safety outcomes from 10 Phase II and III studies which included over 3,990 adult patients with moderate-to-severe plaque psoriasis3

    ·  Affecting 7.5 million Americans, psoriasis can negatively impact daily life and is associated with increased risk for other chronic illnesses4,5

    Basel, January 21, 2015 Novartis today announced the US Food and Drug Administration (FDA) has approved Cosentyx™ (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit interaction with the IL-17 receptor1,2. The approval is based on the efficacy and safety outcomes from 10 Phase II and Phase III studies, including over 3,990 adult patients with moderate-to-severe plaque psoriasis, which demonstrated that Cosentyx resulted in clear or almost clear skin in the majority of patients and had an acceptable safety profile3.

    “The FDA’s approval of Cosentyx signifies a turning point for psoriasis patients, who can now benefit from the first and only approved treatment targeting the IL-17 pathway, which is proven to play a key role in the development of plaque psoriasis,” said David Epstein, Division Head, Novartis Pharmaceuticals. “This important milestone will now allow patients to receive a treatment that has the proven ability to offer clear or almost clear skin.”

    The FDA approval follows the unanimous vote by the FDA Advisory Committee in October 2014. Additionally, in January 2015, the European Commission (EC) approved Cosentyx as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

    Affecting 7.5 million Americans and more than 125 million people worldwide4-6, psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain and may negatively impact daily life7-9. Nearly 35% of psoriasis patients suffer from moderate-to-severe plaque psoriasis10. Research shows IL-17A plays an important role in driving the body’s immune response in disorders such as moderate-to-severe plaque psoriasis11-13. Cosentyx selectively binds to IL-17A, inhibiting its activity1,2.

    The Phase III clinical program included four placebo-controlled studies which examined Cosentyx 300 mg and 150 mg in patients with moderate-to-severe plaque psoriasis3. In these studies, Cosentyx met all primary and key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA) 0/1 responses, showing significant skin clearance at Week 123. PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body. Treatment efficacy is assessed by the reduction of the score from baseline (i.e. a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90). PASI 90 is a higher standard of skin clearance compared to PASI 753.

    About Psoriasis
    Affecting 7.5 million Americans and more than 125 million people worldwide4-6, psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain7-9. Patients reported these symptoms can negatively impact their quality of life, both psychosocially and physically, which makes daily functioning difficult4. Additionally, patients with psoriasis are at increased risk for other chronic illnesses4,5.

    About Cosentyx Clinical Trial Program
    The approval of Cosentyx is based on the safety and efficacy outcomes from 10 Phase II and Phase III studies which included over 3,990 patients with moderate-to-severe plaque psoriasis3. This included the four pivotal Phase III trials - ERASURE, FIXTURE, FEATURE and JUNCTURE14.

    In the Phase III program for Cosentyx (300 mg), the overall safety profile of Cosentyx was favorable, with minimal differences seen between etanercept and ustekinumab in head-to-head comparison14,15. 

    About Cosentyx (secukinumab)
    Cosentyx (secukinumab, previously known as AIN457) is a human monoclonal antibody (mAb) that selectively binds to and inhibits interleukin-17A (IL-17A)1,2.  It is the first IL-17A inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy).

    In addition to the US, Cosentyx has been approved in the EU and Australia for the treatment of moderate-to-severe plaque psoriasis and in Japan for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA).

    In addition to psoriasis, Cosentyx is also in clinical trials for the treatment of PsA and ankylosing spondylitis (AS). Global regulatory applications for secukinumab in AS and PsA are planned for 2015.

  • Full Press Release

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.


Media Contacts